Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
- Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
- Currently, only a handful of adjuvants are available for human use in licensed vaccines.
- Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
- Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.